Payment overview · 2025
General Payments
$146.71
9 reported records · 5 companies
Healthcare provider profile · identity verified
Ehab Ali, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DEFIANCE, OH · NPI 1346680907
Verified facts
What the public records show
CMS Open Payments records show Ehab Ali, M.D. received $146.71 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 34.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.88 | 34.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.20 | 28.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.99 | 13.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.64 | 13.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.00 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.71 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.88 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.88 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.20 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 233 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
233 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 750 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 444 | 92 |
| Lisinopril | Lisinopril | 425 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 96 |
| Potassium Chloride | Potassium Chloride | 340 | 53 |
| Furosemide | Furosemide | 300 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 297 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 289 | 64 |
| Omeprazole | Omeprazole | 278 | 78 |
| Metformin Hcl | Metformin Hcl | 261 | 66 |
| Gabapentin | Gabapentin | 258 | 55 |
| Eliquis | Apixaban | 233 | 37 |
| Trazodone Hcl | Trazodone Hcl | 230 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 45 |
| Buspirone Hcl | Buspirone Hcl | 197 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 52 |
| Losartan Potassium | Losartan Potassium | 185 | 49 |
| Famotidine | Famotidine | 182 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 45 |
| Mirtazapine | Mirtazapine | 143 | 26 |
| Carvedilol | Carvedilol | 139 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 54 |
| Simvastatin | Simvastatin | 134 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 27 |
| Donepezil Hcl | Donepezil Hcl | 120 | 22 |
| Tramadol Hcl | Tramadol Hcl | 119 | 26 |
| Lorazepam | Lorazepam | 106 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 100 | 13 |
| Sertraline Hcl | Sertraline Hcl | 95 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 94 | 15 |
| Baclofen | Baclofen | 93 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 13 |
| Pregabalin | Pregabalin | 90 | 25 |
| Divalproex Sodium | Divalproex Sodium | 88 | 13 |
| Glimepiride | Glimepiride | 86 | 24 |
| Clonazepam | Clonazepam | 85 | 14 |
| Montelukast Sodium | Montelukast Sodium | 85 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 77 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 20 |
| Spironolactone | Spironolactone | 71 | 15 |
| Alprazolam | Alprazolam | 70 | 17 |
| Allopurinol | Allopurinol | 69 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 64 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 64 | 12 |
| Celecoxib | Celecoxib | 63 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 62 | 13 |
| Risperidone | Risperidone | 62 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 60 | 11 |
| Bupropion Xl | Bupropion Hcl | 59 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 59 | suppressed |
| Memantine Hcl | Memantine Hcl | 59 | suppressed |
| Prednisone | Prednisone | 59 | 33 |
| Primidone | Primidone | 59 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 16 |
| Atenolol | Atenolol | 57 | 13 |
| Metformin Hcl Er | Metformin Hcl | 53 | 16 |
| Azithromycin | Azithromycin | 52 | 40 |
| Bumetanide | Bumetanide | 52 | 16 |
| Metolazone | Metolazone | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 13 |
| Ezetimibe | Ezetimibe | 48 | 17 |
| Ozempic | Semaglutide | 48 | suppressed |
| Xarelto | Rivaroxaban | 46 | 11 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Jardiance | Empagliflozin | 45 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Torsemide | Torsemide | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 16 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 20 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Finasteride | Finasteride | 37 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 18 |
| Gemtesa | Vibegron | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 16 |
| Cefdinir | Cefdinir | 31 | 20 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 30 | suppressed |
| Meloxicam | Meloxicam | 29 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 19 |
| Valsartan | Valsartan | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Repatha Syringe | Evolocumab | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 17 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Estradiol | Estradiol | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Klayesta | Nystatin | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.71 · 9 records | Amgen Inc. | Cologuard Collection Kit, ELIQUIS, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error